LEO Pharma Highlights Chronic Hand Eczema Burden with New Data at ESCD 2026
Event summary
- LEO Pharma presents new data on chronic hand eczema (CHE) at ESCD 2026, highlighting disease burden and unmet needs.
- DELTA FORCE study shows 25% of severe CHE patients took sick leave in the past year, with delgocitinib improving work productivity.
- DELTA TEEN trial reveals substantial impact on adolescents' school life and daily activities, underscoring treatment gaps.
The big picture
LEO Pharma's data presentations at ESCD 2026 underscore the significant societal and economic impact of chronic hand eczema, positioning delgocitinib as a potential solution for unmet needs in both adults and adolescents. The focus on work productivity and school life disruption highlights the broader implications of CHE beyond individual health, aligning with trends toward holistic patient outcomes in dermatology.
What we're watching
- Regulatory Approvals
- The pace at which Anzupgo® gains approval in additional markets beyond its current seven.
- Clinical Efficacy
- Whether delgocitinib's demonstrated improvements in work productivity and quality of life will drive adoption among severe CHE patients.
- Market Competition
- How LEO Pharma differentiates Anzupgo® from existing treatments as it targets the chronic hand eczema market.
Related topics